Table 8.

Impact of resveratrol on the expression of genes in the context of cancers of the reproductive system

Type of cancer	Dose range	Cell line	Target	Pathway	Function	Refs.
In vivo studies
Prostate Cancer (PCa)	50 mg/kg 5–100 μM,	DU145, PC3M, 293 T	MTA1, HDAC, ERK1/2, HDAC1, HDAC2, Lamin-A, myc, Flag	PTEN, AKT	RVT by regulating the PTEN/AKT pathway via inhibiting the MTA1/HDA unit could affect the progression and survival pathways of prostate cancer	[76]
In vitro studies
PCa	25–200 μM	LNCaP, RWPE-1, LNCaP-B	ARV7, Bax, Bcl-2, AR	PI3K/AKT	RVT via PI3K/AKT pathway and ARV7 could promote apoptosis in LNCaP prostate cancer cells	[79]
PCa	0–50 μM	PC-3	E-cadherin, Vimentin, Bax, Bcl-2, Caspase-3/9	PI3K/AKT	RVT via downregulating the PI3K/AKT pathway could suppress the EMT in PC-3 cells	[80]
Ovarian Cancer	50 mM	PA-1, OVCAR3, MDAH2774, SKOV3, PBMC, RBC, OSE1, OSE2	P70s6K, mTOR, 4EBP1, GLUT2, GLUT3, GLUT4, GLUT1	AKT	RVT via AKT/GLUT1 axis could induce apoptosis in ovarian cancer cells by impairing glucose uptake	[77]
Ovarian Cancer	0‑200 μM	A2780, SKOV3	Caspase-3	Notch1/PTEN/AKT	RVT via notch1/PTEN/AKT signaling could induce cell death in ovarian cancer cells	[78]